Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$5.78 ▲ +0.12
(+2.12%)
MKT CAP: $2.3M • VOL: 14.75M
52W L $0 52W H $173
ROARABLE / RQD
D- • 35/100
PIOTROSKI
3 / 9
NUWE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.3M | $8.7M | $8.9M |
| YoY Revenue Growth % | -5.4% | -1.4% | — |
| Gross Profit | $5.1M | $5.7M | — |
| Gross Margin % | 62.0% | 64.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.1M | -$11.0M | -$17.6M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$17.5M | -$11.2M | -$20.2M |
| EBITDA (Normalized) | -$11.0M | -$10.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.8M | -$9.6M | -$17.9M |
| Capital Expenditures (CapEx) | $90.0K | $60.0K | — |
| Free Cash Flow (FCF) | -$10.9M | -$9.7M | -$17.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.1M | $5.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.6M | $6.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NUWE.